PXD078020 is an
original dataset announced via ProteomeXchange.
Dataset Summary
| Title | Identification of novel HLA class I-restricted hepatitis B virus peptides and their modulation by peptide editor TAPBPR |
| Description | Hepatitis B virus (HBV) is the leading cause of hepatocellular carcinoma and infections remain a substantial global health problem for which no curative therapy exists. As cytotoxic CD8+ T lymphocytes are the principal effectors of natural HBV resolution, there is considerable interest in discovering novel HBV epitopes that are presented for immune recognition. Current knowledge of HBV-derived peptide presentation to CD8+ T cells is largely dominated human leukocyte antigen (HLA)-A*02:01. Our aim was to characterise novel HBV-derived peptides presented on HLA-B and -C molecules, particularly allotypes that are prevalent in regions with high HBV infection rates. Additionally, we sought to determine if the recently discovered major histocompatibility complex class I (MHC-I) peptide editor TAPBPR modulated expression of HBV-derived epitopes. To discover new HBV-derived epitopes, immunopeptidomic analysis was performed on cells expressing single HLA class I molecules transduced to express individual HBV proteins. Peptide binding assays were used to validate HLA binding of selected peptides. To determine the effect of TAPBPR on the HBV peptidome, immunopeptidomic analysis was performed on either wild-type HeLa cells expressing HBV proteins or their TAPBPRKO counterpart. The results were validated using TAPBPR peptide-exchange assays. We identified 28 novel HBV-derived peptides presented on HLA class I. Importantly, 22 of the newly discovered HBV-derived peptides were identified on cells expressing HLA-B*08:01, -B*15:03, -B*35:01, -C*06:02 and -C*12:03. Additionally, TAPBPRKO HeLa cells presented four additional and novel HBV-derived peptides. This work presents a substantial expansion of the HLA-B and HLA-C-restricted HBV-derived peptides described in the Immune Epitope Database (IEDB). Additionally, this work represents the first indication that TAPBPR shapes not only the cellular but also the viral peptide repertoire presented on MHC-I molecules. |
| HostingRepository | PRIDE |
| AnnounceDate | 2026-07-15 |
| AnnouncementXML | Submission_2026-07-15_05:53:14.049.xml |
| DigitalObjectIdentifier | |
| ReviewLevel | Peer-reviewed dataset |
| DatasetOrigin | Original dataset |
| RepositorySupport | Unsupported dataset by repository |
| PrimarySubmitter | Jens Bauer |
| SpeciesList | scientific name: Homo sapiens (Human); NCBI TaxID: NEWT:9606; |
| ModificationList | monohydroxylated residue |
| Instrument | Orbitrap Fusion Lumos |
Dataset History
| Revision | Datetime | Status | ChangeLog Entry |
| 0 | 2026-05-05 11:40:50 | ID requested | |
| ⏵ 1 | 2026-07-15 05:53:14 | announced | |
Publication List
| Dataset with its publication pending |
Keyword List
| submitter keyword: Immunopeptidomics, HLA, TAPBPR, MHC |
Contact List
| Juliane Sarah Walz |
| contact affiliation | Department of Peptide-based Immunotherapy, Institute of Immunology, University and University Hospital Tübingen, Tübingen, Germany |
| contact email | juliane.walz@med.uni-tuebingen.de |
| lab head | |
| Jens Bauer |
| contact affiliation | Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, Tübingen, Germany |
| contact email | j.bauer@uni-tuebingen.de |
| dataset submitter | |
Full Dataset Link List
Dataset FTP location
NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2026/07/PXD078020 |
| PRIDE project URI |
Repository Record List
[ + ]
[ - ]
- PRIDE
- PXD078020
- Label: PRIDE project
- Name: Identification of novel HLA class I-restricted hepatitis B virus peptides and their modulation by peptide editor TAPBPR